Latest market price
92.24
-5.32-5.45%
OverviewShort InterestFilings
KNSAQT77Kiniksa Pharmaceuticals International, plc·NASDAQ
92.24-5.45%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
CORT-5.62%$81.12LQDA+0.16%$45.06PBH+0.64%$49.06RPRX+1.90%$67.18IBRX-5.15%$8.29SYRE-2.43%$96.56UHS-0.32%$176.05TXG-14.03%$70.11
Snapshot
Index—P/E70.41EPS (ttm)1.31Insider Own5.70%Shs Outstand78.57MPerf Week20.21%
Market Cap7.25BForward P/E45.14EPS next Y2.04Insider Trans-0.18%Shs Float75.12MPerf Month22.63%
Enterprise Value6.68BPEG1.53EPS next Q—Short Float5.01%Perf Quarter25.65%
Income109.00MP/S7.66EPS this Y50.03%Short Ratio6.41Perf Half Y66.89%
Sales946.00MP/B10.21EPS next Y39.86%ROA11.14%Short Interest3.76MPerf YTD123.61%
Book/sh9.04P/C12.74EPS next 5Y46.10%ROE17.27%52W High98.48 -6.34%Perf Year146.76%
Cash/sh7.24P/FCF36.79EPS past 3/5Y-33.93% —ROIC12.30%52W Low36.56 152.30%Perf 3Y508.04%
Dividend Est.—EV/EBITDA46.09Sales past 3/5Y45.52% —Gross Margin54.26%Volatility7.90% 4.77%Perf 5Y760.45%
Dividend TTM—EV/Sales7.06EPS Y/Y TTM191.11%Oper. Margin13.79%ATR (14)4.71Perf 10Y—
Dividend Ex-Date—Quick Ratio3.35Sales Y/Y TTM57.93%Profit Margin11.58%RSI (14)62.98Recom2.00
Dividend Gr. 3/5Y—Current Ratio3.91EPS Q/Q143.48%SMA2013.04%Beta0.08Target Price93.00
Payout0.00%Debt/Eq0.01Sales Q/Q58.01%SMA5016.53%Rel Volume2.11Prev Close97.56
Employees366LT Debt/Eq0.01EarningsFeb 23SMA20053.21%Avg Volume622.59KPrice92.24
IPO DateMay 24, 2018Option/ShortYes / YesEPS/Sales Surpr.50.95% 9.71%Net Debt/EBITDA-3.90Volume1,316,323Change-5.45%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-28-26ReiteratedGoldman SachsBuy$90 → $101
Jul-30-26ReiteratedGoldman SachsBuy$75 → $90
Jul-29-26ReiteratedWedbushOutperform$72 → $99
Jul-29-26ReiteratedCanaccord GenuityBuy$62 → $98
Jul-23-26ReiteratedGoldman SachsBuy$55 → $75
Jul-13-26ReiteratedWells FargoOverweight$34 → $74
Jun-29-26ReiteratedWedbushOutperform$59 → $72
Apr-29-26ReiteratedWedbushOutperform$58 → $59
Apr-28-26ReiteratedJefferiesBuy$54 → $71
Apr-16-26ReiteratedWedbushOutperform$50 → $58
Latest News· Times ET
Oct-27-26
Oct-27-2601:51PM
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investorsfool.com
12:06PM
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Callmarketbeat.com
11:30AM
Gap-Up and Gap-Down Stocks in Today's SessionChartMill
11:30AM
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcriptseekingalpha.com
09:50AM
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimateszacks.com
07:30AM
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Executionglobenewswire.com
Oct-22-26
Oct-22-2604:01PM
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026globenewswire.com
Oct-21-26
Oct-21-2604:01AM
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High – Still a Buy?defenseworld.net
Oct-17-26
Oct-17-2611:11AM
GeneDx Holdings And 2 Other Top Healthcare StocksYahoo
Oct-16-26
Oct-16-2603:47AM
10,232 Shares of Kiniksa Pharmaceuticals International, plc $KNSA Acquired by B. Riley Wealth Advisors Inc.defenseworld.net
02:59AM
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)defenseworld.net
Oct-13-26
Oct-13-2607:10AM
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pairs Strong Growth With a High-Quality Technical SetupChartMill
Oct-02-26
Oct-02-2608:41AM
Kiniksa Pharmaceuticals (NASDAQ:KNSA): Affordable Growth Backed by Accelerating EarningsChartMill
Sep-28-26
Sep-28-2607:01AM
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pairs High Growth Momentum With a Breakout SetupChartMill
Sep-25-26
Sep-25-2604:15AM
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Consensus Price Target of $87.38 According to Brokeragesdefenseworld.net
Company

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue946678423270—————
Cost of Goods Sold Incl. D&A4333076157—————
Gross Profit513370362214—————
Selling, General and Administrative Excl. Other247196168129—————
Research and Development1369711276—————
Other Operating Expense0012834—————
Operating Income13077-46-25—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)161299—————
Net Income Before Taxes14689-36-17—————
Income Taxes37307-31—————
Consolidated Net Income10959-4314—————
Net Income From Continuing Operations10959-4314—————
Net Income10959-4314—————
EPS (Recurring)1.430.80-0.600.20—————
EPS (Basic, Before Extraordinaries)1.430.80-0.600.20—————
EPS (Diluted)1.310.75-0.600.20—————
EBITDA14590-34-14—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio70.4155.00—87.70—————
Price To Sales Ratio7.614.503.324.55—————
Gross Margin54.2354.5785.5879.26—————
Operating Margin13.7411.36-10.87-9.26—————
Net Margin11.528.70-10.175.19—————
Shares Outstanding78747170—————
Market Capitalization7,1953,0531,4041,228—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$107.24$86.27$65.30$44.33$23.36● Close Price0.00M6.77M13.53M20.30M27.07MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Megna Michael RCHIEF ACCOUNTING OFFICERSep 03 '26Sale80.304,600369,38029,062Sep 03
Ragosa MarkCHIEF FINANCIAL OFFICERSep 01 '26Option Exercise0.009,104025,258Sep 03
Patel Sanj KCHAIRMAN & CEOSep 01 '26Option Exercise0.0062,6360107,492Sep 03
Paolini John F.CHIEF MEDICAL OFFICERSep 01 '26Option Exercise0.008,328073,951Sep 03
Moat RossCHIEF OPERATING OFFICERSep 01 '26Option Exercise0.008,285020,314Sep 03
Megna Michael RCHIEF ACCOUNTING OFFICERSep 01 '26Option Exercise0.0011,496039,193Sep 03
Levy Richard SDirectorAug 01 '26Option Exercise0.00403022,359Aug 04
Cole G BradleyDirectorJul 29 '26Sale81.433,673299,09211,672Jul 31
Malley ThomasDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
Levy Richard SDirectorMay 29 '26Option Exercise0.002,799021,956Jun 02
Cole G BradleyDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
Quart Barry DDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
Popovits Kimberly JDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
McCain Tracey LDirectorMay 29 '26Option Exercise0.002,799015,345Jun 02
Paolini John F.CHIEF MEDICAL OFFICERMay 01 '26Option Exercise10.3658,424605,273124,047May 05
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.